Musculin does not modulate the disease course of Experimental Autoimmune Encephalomyelitis and DSS colitis

Anna Vanni, Alberto Carnasciali, Alessio Mazzoni, Edda Russo, Parham Farahvachi, Leandro Di Gloria, Matteo Ramazzotti, Giulia Lamacchia, Manuela Capone, Lorenzo Salvati, Laura Calosi, Daniele Bani, Francesco Liotta, Lorenzo Cosmi, Amedeo Amedei, Clara Ballerini, Laura Maggi,*, Francesco Annunziato

Department of Experimental and Clinical Medicine, University of Florence, Florence 50139, Italy
Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence 50139, Italy

ARTICLE INFO

Keywords:
Multiple sclerosis
EAE
Inflammation
Th17
Musculin
IL-2
DSS
Colitis
Microbiota

ABSTRACT

Previous evidences show that Musculin (Msc), a repressor member of basic helix-loop-helix transcription factors, is responsible in vitro for the low responsiveness of human Th17 cells to the growth factor IL-2, providing an explanation for Th17 cells rarity in inflammatory tissue. However, how and to what extent Musculin gene can regulate the immune response in vivo in an inflammatory context is still unknown. Here, exploiting two animal models of inflammatory diseases, the Experimental Autoimmune Encephalomyelitis (EAE) and the dextran sodium sulfate (DSS)-induced colitis, we evaluated the effect of Musculin gene knock-out on clinical course, performing also a deep immune phenotypical analysis on T cells compartment and an extended microbiota analysis in colitis-sick mice. We found that, at least during the early phase, Musculin gene has a very marginal role in modulating both the diseases. Indeed, the clinical course and the histological analysis showed no differences between wild type and Msc knock-out mice, whereas immune system appeared to give rise to a regulatory milieu in lymph nodes of EAE mice and in the spleen of DSS colitis-sick mice. Moreover, in the microbiota analysis, we found irrelevant differences between wild type and Msc knock-out colitis-sick mice, with a similar bacterial strains’ frequency and diversity after the DSS treatment. This work strengthened the idea of a negligible Msc gene involvement in these models.

1. Introduction

Chronic inflammatory disorders are a heterogeneous group of diseases characterized by uncontrolled, persistent inflammation at target organs, leading to impaired functionality and disability. Deregulated innate and adaptive immune responses are responsible for sustained inflammation, and targeting inflammatory cells, or their products, is an effective strategy in alleviating disease symptoms [1]. For this reason, understanding the basic biology of immune cells activation and regulation is of relevant importance to define which pathways are altered in chronic inflammation, thus potentially providing novel targets for therapy.

Transcription factors belonging to the basic helix-loop-helix (bHLH) family are a considerable number of proteins involved in a wide array of developmental processes and are master regulators of lymphoid cells' development and differentiation [2]. They commonly work as homo- or hetero-dimers and can activate/suppress gene expression. E proteins HEB and E2A, which belong to the bHLH family, promote thymocyte development at the double positive stage [3], while their activity must be down-regulated to proceed to the single positive stage [4-6]. Among bHLH members with suppressive activity, Id2 and Id3 are the most studied. These transcription factors play primary roles in CD4+ and CD8+...
T cell development [7,8]. Another bHLH transcription factor with suppressing activity is *Musculin* (Msc, also known as MyoR or ABF-1), which showed the capability to block skeletal myogenesis by repressing MyoD transcription factor [9], to play a protective role for kidney cells in a renal failure murine model [10] and to establish normal cardiac conduct in a Gata4-dependent transcriptional circuit [11]. Furthermore, a prominent Msc role in immune system modulation has been suggested after its expression has been described in B cell lymphoma, where it is involved in decreasing the B lymphocyte proliferation and survival [12]. Likewise, Msc controls also T cell proliferation since the loss of function mutations of this gene has been observed in anaplastic large cells lymphoma (ALCLs), a common group of T cells non-Hodgkin lymphomas. In this setting, the impaired Msc functionality in T cells leads to unrestrained Myc activity, thus promoting cell cycle progression [13]. A similar role has been demonstrated also in Th17 cells, where Msc can suppress their IL-2 mediated proliferation by activating a complex mechanism of serine phosphorylation that ultimately impairs STAT5b activity [14]. Importantly, this finding might contribute to explain why Th17 cells have been found to be rare in the inflamed sites of several animal models [15-17] or in human inflammatory and autoimmune diseases, such as Crohn’s disease and multiple sclerosis [18-20]. In addition, Msc has been recently identified also as a critical factor for induced-Treg (iTreg) development in mice, by suppressing the Th2 differentiation program [21]. With these premises, Msc seems to play a primary role in lymphoid cell differentiation and function. However, how Msc regulates the immune responses of different cell subsets in the pathogenic, inflammatory, context remains to be completely understood. For this reason, in this work we studied the effect of Msc deletion in the development of two well-established murine models of human chronic inflammatory disorders, the Experimental Autoimmune Encephalomyelitis (EAE) and dextran sodium sulfate (DSS)-induced colitis, analyzing for this last model also the intestinal microbiota.

2. Materials and methods

2.1. Experimental animals

We used non-littermate C57BL/6-B129 wild type (WT, total n=17) and Msc−/− (KO, total n=18) mice, co-housed in the same breeding facility (Charles River, ITALY). During each experimental session, animals were co-housed at the CeSaL animal house of the University of Florence, in Makronol cages according to the genetic background, with free access to food and water and kept at 23 °C with a 12 h light/dark cycle. Every manipulation of the animals was executed according to the guidelines of the European community for animal care (DL 116/92, application of the European Communities Council Directive 2010/63/EU) and approved by the Committee for Animal Care (DGSAF, Italy, Authorization no. 798/2018-FR)∗.

2.2. EAE induction

EAE was induced in 8 to 10 weeks-old female mice (WT, n=17) and Msc−/− (KO, n=18) by subcutaneous (s.c.) injection of 200 µg of myelin oligodendrocyte glycoprotein MOG35-55 peptide (MEVG-WYRSPFSRVVHLRNYGK, purity 85%; Espikem, Florence, Italy) in Phosphate Buffer Saline solution (PBS, Carlo Erba Reagents S.r.l., Italy), emulsified with an equal volume of complete Freund’s adjuvant (CFA, Sigma) supplemented with 7 mg/ml L1 *Mycobacterium tuberculosis* H37Ra (Difco Laboratories, USA). *Bordetella pertussis* toxin (500 ng) was administered by i.p. injection at days 0 and 2 post immunization (Merck, Germany). All the experiments with animals were performed blinded and mice were randomly assigned to the experimental groups. EAE-induced mice were scored daily for clinical signs of disease, according to the following scale: (0) normal mouse, no overt signs of disease; (1) limp tail or hind limb weakness but not both; (2) limp tail and hind limb weakness; (3) partial hind limb paralysis; (4) complete hind limb paralysis; (5) moribund state or death by EAE: sacrifice for humane reasons.

2.3. DSS colitis induction

Colitis was induced in 8 to 10 weeks-old male mice (WT, n=6) and Msc−/− (KO, n=6) by feeding them with 3% DSS 40,000 kDa (Sigma, Germany) in water for 8 days. Mice were daily weighted until the day of sacrifice.

2.4. Feces collection and 16S rRNA V3-V4 region gene sequencing and sequencing data analysis

Fresh feces from four WT and four KO mice were collected at T0 (pre-DSS treatment) and T1 (post-DSS treatment) and were stored at −80 °C until analysis. Fecal bacterial DNA extraction was performed as described in our previous study [23]. The 16S rRNA gene V3-V4 region was amplified from genomic DNA using the universal bacterial primers 341F and 805R. The amplicons were normalized, pooled and sequenced on the Illumina MiSeq sequencer. Libraries were prepared using Library Quant Kit Illumina GA revised primer-SYBR Fast Universal (KAPA, Wilmington, MA, USA) and sequenced for 600 cycles on an Illumina MiSeq using the MiSeq Reagent Kit (Illumina, San Diego, CA, USA) at IGA technology service (Udine). Primer trimming, denoising, high-quality sequence merging and ASV delineation were performed using Cutadapt and DADA2 in the QIIME2 v2021.4 environment. The scikit-learn classifier retrained on the V3-V4 region of the SILVA138 database has been used for the taxonomic assignment [24]. Further details regarding sequence processing and analysis is available on GitHub (see https://github.com/Leandrod94/Papers). Microbiota raw and processed data has been publicly deposited in NCBI GEO database under accession GSE223002.

2.5. Histology

Immediately after the sacrifice, the spinal cord from EAE mice and the colon from colitis-sick mice were carefully removed and put in PBS for 3 h. Later, tissue samples were fixed with 4% paraformaldehyde (PFA) and paraffin-embedded and sectioned with a microtome in 5 µm thick slices. Alternatively, tissue sections were embedded in Optimal Cutting Temperature compound (OCT) (Bio-Optica, Italy), frozen at −80 °C, and cut with a micrometre-cryostat. Afterwards, slices were stained with Hematoxylin and Eosin (H&E) or Luxol Fast Blue/Periodic Acid-Schiff (LFB/PAS), following standard protocols. The number of inflammatory infiltrates and demyelinated areas in the spinal cord were evaluated by a manual count on a selected or fixed area in EAE mice, using a 4X magnification with microscope (Leica DM750, Germany). With the same approach, inflammatory infiltrates into the colonic mucosa and submucosal areas were evaluated in colitis-sick mice.

2.6. Tissue processing

After the sacrifice, spleen, inguinal and axillary lymph nodes and spinal cord were carefully removed and promptly put in PBS with Penicillin/Streptomycin 1%. Afterwards, all tissues were smashed on a nylon 22 µm filter (Corning, USA) and different protocols were used for each organ: mononucleated cells were isolated after density gradient centrifugation (Lymphoprep, Stem Cell, USA) from collected splenocytes; cells from lymph nodes directly underwent to flow cytometry staining; spinal cord mononucleated cells were isolated by means of Percoll (GE Healthcare, USA) density gradient centrifugation.
2.7. Flow cytometry

Staining for intranuclear FoxP3 and Ki-67 was performed on each organ following manufacturer’s protocol (e-Bioscience, USA) using fluorochrome-conjugated antibodies listed in Table 1. Intracellular staining was performed by restimulating cells ex vivo with PMA and Ionomycin. After two hours of incubation at 37 °C, 5% CO2, cells were treated with Brefeldin-A (5 µg/mL), followed by additional 3 h of incubation. Finally, cells were fixed and stained using fluorochrome-conjugated antibodies listed in Table 2. Samples were acquired on a BD LSR II flow cytometer (BD Biosciences) with FACS Diva Software and analyzed by FlowJo Software. Membrane staining was performed using the antibodies listed in Table 3.

2.8. Absolute cell number

Absolute cells number from the spleen and colon of WT and KO mice were counted using a MACS Quant (Miltenyi Biotec, Germany).

3. Results

3.1. Msc knock-out did not impact the EAE clinical outcome and histological features

To understand if Msc deletion affects EAE outcome, we firstly evaluated the clinical progression of Msc−/− (n=18) compared to WT B6/129 (n=17) EAE mice, attributing a clinical score which ranges from 1 to 5, as described in the methods section. The clinical score showed no differences between the groups (Fig. 1A) and the disease developed equally in both conditions, with initial disability occurring around day 8 post-immunization (Fig. 1A). The kinetics of disease development was similar for Msc−/− and WT mice, with a maximum score on day 15, requiring to euthanize mice for the high score reached. Furthermore, clinical observations were corroborated by histological analysis performed on spinal cord sections, where hematoxylin and eosin staining showed that the extent of inflammatory infiltrates was comparable between Msc−/− mice and WT (Fig. 1 B–E and J), as well as demyelinated areas evaluated by Luxol Fast Blue staining (Fig. 1 F–I and K).

3.2. WT and Msc−/− mice showed comparable numbers of CNS immune infiltrates

As EAE is an autoimmune disease characterized by focal infiltration of immune cells in the CNS [25], we performed an extended flow cytometry phenotypical analysis, in order to define the composition of the immune subpopulations throughout the CNS, using the spleen and lymph nodes as reference organs. Flow cytometric analysis allowed the characterization of lymphoid and mieloid cells. Infiltrates were counted using a MACS Quant (Miltenyi Biotec, Germany).

Data obtained so far showed no major differences in immune cells infiltrating the spinal cord in Msc−/− mice compared to WT. In order to characterize the functional properties of T cells in our experimental group, we monitored the expression of Ki-67, a proliferation marker, and cytokines secretion in WT mice (Fig. 2A). The same analysis was also performed on CD8+ T cells. We observed comparable levels of all analyzed cytokines in CNS-derived cells from both WT and Msc−/− mice (Fig. 3D). Notably, Msc−/− CD8+ T cells from lymph nodes produced lower IL-10 and IFN-γ than WT mice (Fig. 3H), while no difference in cytokines production was observed in CD8+ T cells derived from the spleen in both experimental groups (Fig. 3F).

Table 1 List of fluorochrome-conjugated antibodies used for intracellular staining of FoxP3 and Ki-67.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Fluorochrome</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki-67</td>
<td>FITC</td>
<td>SolA15</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD4</td>
<td>PE</td>
<td>RM4-5</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD3</td>
<td>SB600</td>
<td>145-2C11</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD8</td>
<td>BV711</td>
<td>53-6.7</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>FoxP3</td>
<td>eFluor450</td>
<td>FJK-164</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>L/D</td>
<td>Fixable Viability Stain 780</td>
<td>FJK-164</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>CD25</td>
<td>APC</td>
<td>7D4</td>
<td>Miltenyi Biotec</td>
</tr>
</tbody>
</table>

Table 2 List of fluorochrome-conjugated antibodies used for flow cytometric evaluation of T cells cytokine production.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Fluorochrome</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL17</td>
<td>Alexa Fluor 488</td>
<td>TC11-18H10</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>IL10</td>
<td>PE</td>
<td>JES516E3</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>IFNγ</td>
<td>PerCP-Cy5.5</td>
<td>XMG1.2</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD3</td>
<td>SB600</td>
<td>145-2C11</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD8</td>
<td>BV711</td>
<td>53-6.7</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>L/D</td>
<td>Fixable Viability Stain 780</td>
<td>RM4-5</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD4</td>
<td>PE-Cy7</td>
<td>RM4-5</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>IL22</td>
<td>APC</td>
<td>IL22JOP</td>
<td>eBioscience™</td>
</tr>
</tbody>
</table>

Table 3 List of all fluorochrome-conjugated antibodies used for flow cytometric immunophenotyping of lymphoid and mieloid cells.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Fluorochrome</th>
<th>Clone</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD19</td>
<td>FITC</td>
<td>6D5</td>
<td>Miltenyi Biotec</td>
</tr>
<tr>
<td>CD8</td>
<td>PE</td>
<td>53-6.7</td>
<td>Miltenyi Biotec</td>
</tr>
<tr>
<td>Siglec-F</td>
<td>PE</td>
<td>E50-2440</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>LY6G</td>
<td>PerCP-Cy5.5</td>
<td>1A8</td>
<td>BioLegend</td>
</tr>
<tr>
<td>Ly6C</td>
<td>Pacific Blue</td>
<td>HKL-4</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD3</td>
<td>APC-eFluor780</td>
<td>145-2C11</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD4</td>
<td>PE-Cy7</td>
<td>RM4-5</td>
<td>eBioscience™</td>
</tr>
<tr>
<td>CD64</td>
<td>APC</td>
<td>X54.5/7.1</td>
<td>eBioscience™</td>
</tr>
</tbody>
</table>

Msc−/− mice as well as (Fig. 2A). Likewise, comparable cellularity in the two experimental groups was found in the spleen (Fig. 2C and D) and also in the lymph nodes (Fig. 2E and F).

3.3. Functional characterisation of T cells showed a rising regulatory milieu in the peripheral lymph nodes of Msc−/− mice

We also evaluated by flow cytometry the frequency of Treg lymphocytes, defined as Foxp3+ CD25+ in Msc−/− and WT mice. Of note, Msc−/− mice showed a significant higher frequency of Treg in lymph nodes than WT mice (Fig. 2G). Conversely, the spleen and CNS showed a comparable percentage of regulatory T cells between the two experimental groups (Fig. 2G).
3.4. Musculin did not affect DSS colitis clinical outcome and cytokines production in the colon

Further, we investigated, with the same approach, the involvement of Msc gene in another condition of chronic inflammation, the DSS-induced colitis model for human intestinal bowel disease. After inducing colitis in WT (n = 6) and Msc/– mice (n = 6) B6/129 mice with dextran sulfate sodium, we followed the weight changes every day, observing a gradual weight reduction from day 5 after treatment beginning, evolving with similar kinetics in both groups, with a maximum reached on day 8. The evaluation of body weight loss showed no differences between the analyzed groups (Fig. 4A).

Given that a characteristic of intestinal inflammation is the thickening and shortening of the large bowel, we measured in mice the colon weight/length ratio. In accordance with the similar weight loss, Msc/– mice showed equivalent values of colon weight/length ratio to WT (Fig. 4B). Clinical observations were partially confirmed by histological analysis in the colon mucosa. Indeed, hematoxylin and eosin staining (Fig. 4C) and the assigned histological score showed a similar mucosal infiltration between the two groups. On the other hand, submucosal infiltration was significantly lower in Msc/– mice (Fig. 4D).

Adopting the same approach used in the EAE model, we investigated the immunological characteristic of DSS treated Msc/– and WT mice. In accordance with a comparable disease course, we observed no differences regarding the immune cell infiltrates in the colon and in the spleen, with similar absolute numbers of myeloid and lymphoid cells, comprising also regulatory T cells, in both the experimental groups (Fig. 5A–D). Moreover, as observed in EAE mice, no differences emerged in FoxP3+CD25+ cells frequency neither in the spleen nor in the colon (Fig. 5E).

We further evaluated the colon infiltrating T cells’ functionality through the Ki-67 expression and the production of cytokines by flow cytometry. No difference was observed in the frequency of both CD4+ and CD8+ T cells expressing Ki-67, suggesting a similar proliferation rate in the two groups (Fig. 6A and B). Likewise, the levels of cytokines produced by CD4+ and CD8+ colon infiltrating T cells were comparable in Msc– and WT mice (Fig. 6C and D). CD8+ T cells obtained from the Msc– spleen produced lower levels of IL-10 and IFN-γ.
cytokines than WT (Fig. 6F). On the other hand, CD4+ T cells showed no differences in the production level of the analyzed cytokines (Fig. 6E).

3.5. Msc knock-out did not shape the gut microbiota composition, regardless genetic background

As DSS destroys the epithelial barrier and leads to diffuse gut inflammation [13], we performed a restricted microbiota study in the same WT (n=4) and Msc−/− (n=4) B6/129 mice, aiming to evaluate potential alterations, attributable to Musculin gene, in the modulation of the gut microbiome-immunity axis, before (T0) and after (T1) DSS treatment.

In order to consider the bacterial diversity among groups (in detail, Group 1: WT-T0; Group 2: KO-T0; Group 3: WT-T1; Group 4: KO-T1), we evaluated the richness and the abundance of microbiota. The alpha diversity parameters, determined by means of Observed, Shannon and Evenness indices, were assessed at both T0 and T1. A trend was observed for Shannon (p=0.057) and Evenness (p=0.057) indices between WT vs Msc−/− mice at T0, with a lower, not significant, alpha diversity for the Msc−/− group (Fig. 7A). Indices were not significantly different between WT and Msc−/− mice at T1 (Fig. 7B). Then, we determined the effect of DSS-induced colitis on microbiota architecture. Comparing T0 vs T1 fecal samples of WT mice, we observed significant differences at the phylum level. Notably, T1 samples were enriched in Proteobacteria, Gammaproteobacteria and Enterobacteriaceae (Phylum, Class and family, respectively) (Fig. 8A). Likewise, we observed significant differences at

Fig. 2. Msc gene knock-out does not impact the absolute cell number in CNS, spleen and lymph nodes in EAE compared to WT EAE mice. Panel shows the absolute cell number belonging to myeloid lineage (A, top, CNS; C, mid, spleen; E, bottom, lymph node) in Msc−/− (n=12, red dots) and WT (n=11, blue dots) or to lymphoid lineage (B, top, CNS; D, mid, spleen; F, bottom, lymph node) in Msc−/− (n=18, red dots) and WT (n=17, blue dots) evaluated by means of a volumetric count at MACSquant® analyzer. (G) Percentage of FoxP3+CD25+ cells in CNS (left), spleen (mid), lymph node (right) in Msc−/− (n=18, red dots) and WT (n=17, blue dots). Horizontal black lines represent the mean value; Mann–Whitney test was used (***p < 0.001).
phylum level in Msc\textsuperscript{-/-} mice. Indeed, T1 samples were enriched in Proteobacteria, Cyanobacteria and Deferribacterota, while a decrease in Actinobacterota was documented (Fig. 8B).

4. Discussion

The purpose of the study was to investigate the effect of Musculin gene deletion in two distinct models of inflammation, establishing a possible causal relationship between Msc deletion and the unleashing of pathogenic immune cells, with a worsening of disease course. Indeed, as antigen-activated T cells are able to cross the BBB and contribute to CNS damage upon the EAE induction, we expected a worsened clinical outcome in Msc\textsuperscript{-/-} mice, as a loss of the gene would have allowed an uncontrolled proliferation of pathogenic antigen-activated autoreactive lymphocytes, without the capability to halt such a wave. However, from a clinical and histological point of view, we failed to demonstrate differences in the clinical outcome, as Msc\textsuperscript{-/-} mice did not show a different disease course compared to the WT counterpart, nor a different inflammatory infiltrate burden throughout the spinal cord, meaning that Msc knock-out was not sufficient to cease either the recruitment toward the CNS of immune cells and the demyelination.

This aspect was further corroborated by the extensive phenotypical analysis of the immune cells in the CNS, spleen and lymph nodes, which showed a comparable qualitative and quantitative distribution of myeloid and lymphoid lineages in all the compartments.

However, Msc has been identified as essential for the development of
regulatory T lymphocytes from naïve T cells in the periphery and Msc<sup>−/−</sup> mice have been shown to be unable to suppress autoreactive T cells response, causing the spontaneous onset of intestinal and lung inflammation with age [21]. Indeed, it has been demonstrated that the Tregs mediate recovery from EAE by controlling the proliferation of effector myelin-reactive T cells and their traffic towards the CNS [26,27]. However, as we sacrificed the animals after 15 days of disease, we could not further force a speculation about a putative effect of the marginal differences seen in the Treg compartment and cytokines production within peripheral organs, limiting the discussion to a general description.

In the second experimental section, we evaluated the effect of Msc gene deletion also in the inflammatory model of DSS-induced colitis, either evaluating the immune system and the microbiota composition of the two experimental groups. In agreement with data obtained in EAE, we did not appreciate differences between colitis-sick WT and Msc<sup>−/−</sup> mice in the disease course. Indeed, the experimental groups showed a similar disease onset, with no alterations in colon weight/length ratio and no differences in function and composition of colon-infiltrating immune cells. Our findings are in contrast with previous studies conducted on DSS colitis mice, where Msc knock-out has been repeatedly associated with a worse disease course, a more severe colonic epithelial

Fig. 4. Msc gene knock-out does not influence the DSS-induced colitis course but slightly affect the mucosal pathology. (A) DSS-induced colitis disease course in WT (n=6, blue line) and Msc<sup>−/−</sup> (n=6, red line) from day 2 until the day of sacrifice. Percentage of the original weight (100%) have been reported each day. Values are reported as mean ± SD. (B) Weight/length ratio of colon from WT (n=6, blue column) and Msc<sup>−/−</sup> (n=6, red column) colitis-sick mice. Means ± SD are reported; Mann-Whitney test was used. (C) Panel shows representative images of colon mucosa stained with hematoxylin and eosin (top, cryostat-cut slices, 20X magnification; scale bar=100 μm), (mid and bottom, paraffin-embedded slices, 20X magnification; scale bar=100 μm) in WT (n=5, left side) and Msc<sup>−/−</sup> (n=5, right side) colitis-sick mice. (D) Histological score evaluated by number of inflammatory infiltrates in a fixed area (7 tissue slices per animal) in WT (n=5, blue column) and Msc<sup>−/−</sup> (n=5, red column). Means ± SD are reported; Mann-Whitney test was used (*p < 0.05).
injury and higher levels of IL-17 and IL-22 produced by colonic cells [28, 29]. Multiple reasons might have contributed to this outcome: first, we used a 3% DSS solution, whereas in comparative studies mice were treated with 4% DSS. More importantly, different techniques and different organs were used for the evaluation of cytokines’ production: indeed, Yu et al. [28] evaluated cytokines amount by ELISA and qRT-PCR in the supernatant from whole colonic tissue or Peyer’s patches/mesenteric lymph nodes, respectively, whereas we only looked at cytokines produced by splenic and lymph nodal T cells by means of intracellular staining at flow cytometer. Moreover, in a brief letter, Yan et al. [30] found a higher production of IL-17A and IL-22 in FACS-sorted memory T cells from Msc−/− mice, but, again, in a different setting from ours. Nonetheless, considering the similar disease progression between the two groups in our experiments, comparable levels of IL-22 in the colon mucosa should not be unexpected, as IL-22 is mainly a cytokine involved in mucosal protection and pathology [31]. Moreover, it is well known the influence of initial microbiota composition in the DSS colitis model, with several studies describing a microbiota-dependent severity in DSS-colitis, even using the same murine strain in repeated conditions [32–34].

Despite we are fully aware of the limitation introduced by lack of using littermate mice, our analysis of the microbiota profile revealed negligible differences between the two groups in the initial microbiota composition, suggesting that the presence/absence of the Musculin gene is not relevant for shaping microbiota composition during DSS establishment and course, regardless mice genetics. Conversely, when we

Fig. 5. Msc gene knock-out does not impact the absolute cell number in spleen and colon of Msc−/− compared to WT DSS-colitis mice. Panel shows the absolute cell number belonging to myeloid lineage (A, top left, colon; C, mid left, spleen) in WT (n=3, blue dots) and Msc−/− (n=3, red dots) or to lymphoid lineage (B, top right, colon; D, mid right, spleen) in WT (n=6, blue dots) and Msc−/− (n=6, red dots) mice, evaluated by means of a volumetric count at MACSquant® analyzer. (E) Percentage of FoxP3+ CD25+ cells in colon (left), spleen (right) in WT (n=6, blue dots) and Msc−/− (n=6, red dots). Horizontal black lines represent the mean value; Mann–Whitney test was used.
compared the composition before and after the DSS treatment within the same experimental group, we appreciated a significant diversity, already at the phylum level, with some shared classes and families between WT and Msc$^{-/-}$ mice after DSS administration. Notably, we reported a marked dysbiotic status when comparing T0 vs T1 in both WT and Msc$^{-/-}$ mice, due at least to an increase of the mean Proteobacteria percentage, especially in the Msc$^{-/-}$ group. Interestingly, Proteobacteria is known to be a pro-inflammatory phylum and is often found to be increased in disease inflammatory conditions, such as IBD and DSS-induced colitis models [35–41], promoting the production of excessive pro-inflammatory cytokines [42,43]. Thus, our microbiota analysis reflected immunological data, with irrelevant differences between WT and Msc$^{-/-}$ mice after DSS disease, suggesting a severe impact of Msc gene deletion in modulating colitis course and, on the other hand, the DSS ability to impact the gut microbiota composition within each group, without altering immune cells composition and, in particular, T cells' response.

However, despite the microbiota analysis showed a similar establishment of proinflammatory microbiota during DSS disease, the reduced submucosal cells infiltration might prelude to a faster recovery in Msc$^{-/-}$ mice, as we hypothesize for EAE model. Interestingly, the CD8$^+$ T cells produced less IFN-$\gamma$ and IL-10 in the spleen, an organ not directly interested by the disease, as observed in the lymph nodes of EAE mice. Few studies have focused, so far, on the relevance of CD8$^+$ T cells in colitis model and, among them, Nancey et al. [44] described the expansion of cytotoxic IFN-$\gamma$ producing CD8$^+$ cells in colon draining lymph nodes five days after BALB/c mice were challenged with a sub-optimal dose of 2,4-dinitrobenzene sulfonic acid, in a model of chemically-induced inflammatory colitis closely related to DSS [44]. However, we think that a later evaluation might be useful to highlight the potential Msc involvement in the clinical recovery from the diseases, in order to achieve a wider perspective on Msc role in

---

**Fig. 6.** Msc gene knock-out does not affect the proliferative capability and has a minor impact on cytokines production in CD4$^+$ and CD8$^+$ in spleen and colon in Msc$^{-/-}$ compared to WT DSS-colitis mice. (A) Proliferative capability of T cells expressed as percentage of CD4$^+$ Ki-67$^+$ T cells from spleen WT (n=6, blue dots) and Msc$^{-/-}$ (n=6, red dots) and colon WT (n=6, blue dots) and Msc$^{-/-}$ (n=6, red dots) in DSS mice. (B) Proliferative capability of T cells expressed as percentage of CD8$^+$ Ki-67$^+$ T cells from spleen WT (n=6, blue dots) and Msc$^{-/-}$ (n=6, red dots) and colon WT (n=5, blue dots) and Msc$^{-/-}$ (n=4, red dots) in DSS mice. (C, D) Percentage of total CD4$^+$ or CD8$^+$ (E, F) T cells producing IL-2, IFN-$\gamma$, IL-17 or IL-22 after activation with PMA plus ionomycin and with brefeldin-A in colon (mid), spleen (bottom) in WT (n=6, blue dots) and Msc$^{-/-}$ (n=6, red dots) DSS mice, evaluated by means of intracytoplasmic staining at flow cytometer. Horizontal black lines represent the mean value; Mann–Whitney test was used (*p < 0.05).
inflammatory context.

5. Conclusions

To our knowledge this is the first work addressing the role of Msc in EAE and our results indicated a very marginal role of Msc in EAE both in the onset and the early phase of diseases. More interestingly, the negligible role of Msc gene emerged also in DSS-colitis model, a toxic, chemically induced inflammatory model that does not need the priming with an antigen as the EAE. Here, the study also strengthened the immunological data with the assessment of the microbiota profile, demonstrating an irrelevant Msc role in shaping microbiota composition and, in turn, the immune regulation. In these models, the involvement of other pathological mechanisms implicated in T cell activation and expansion could explain the marginal role of the transcription factor Msc in disease onset. However, further studies to better elucidate the role of this transcription factor in autoimmunity and chronic inflammation are needed.

Declaration of Competing Interest

None.

Acknowledgments

The project has been granted by Multiple Sclerosis Italian Association (AISM) (project number 2017/R/3)

References


